Vita 34 AG
XETRA:V3V
Vita 34 AG
XETRA:V3V
Price:
4.7 EUR
-1.26%
Updated:
May 9, 2024
Vita 34 AG
Cost of Revenue
|
Vita 34 AG
Cost of Revenue Peer Comparison
Comparables:
F
FME
F
FRE
E
1846
SYAB
Competitive Cost of Revenue Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Cost of Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
|
Vita 34 AG
XETRA:V3V
|
Cost of Revenue
-€64.2m
|
CAGR 3-Years
-94%
|
CAGR 5-Years
-49%
|
CAGR 10-Years
-27%
|
|
F
|
Fresenius Medical Care AG & Co KGaA
XETRA:FME
|
Cost of Revenue
-€14.5B
|
CAGR 3-Years
-6%
|
CAGR 5-Years
-5%
|
CAGR 10-Years
-7%
|
|
F
|
Fresenius SE & Co KGaA
XETRA:FRE
|
Cost of Revenue
-€17.2B
|
CAGR 3-Years
13%
|
CAGR 5-Years
6%
|
CAGR 10-Years
-2%
|
|
E
|
Euroeyes International Eye Clinic Ltd
HKEX:1846
|
Cost of Revenue
-HK$378.8m
|
CAGR 3-Years
-13%
|
CAGR 5-Years
-12%
|
CAGR 10-Years
N/A
|
|
|
Synlab AG
XETRA:SYAB
|
Cost of Revenue
-€615.7m
|
CAGR 3-Years
3%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
See Also
What is Vita 34 AG's Cost of Revenue?
Cost of Revenue
-64.2m
EUR
-64.2m
EUR
Based on the financial report for Sep 30, 2023, Vita 34 AG's Cost of Revenue amounts to -64.2m EUR.
What is Vita 34 AG's Cost of Revenue growth rate?
Cost of Revenue CAGR 10Y
-27%
-27%
Over the last year, the Cost of Revenue growth was -10%. The average annual Cost of Revenue growth rates for Vita 34 AG have been -94% over the past three years , -49% over the past five years , and -27% over the past ten years .
You don't have any saved screeners yet
